Apexigen, Inc.

Apexigen, Inc. (Nasdaq: APGN) is a clinical-stage biopharmaceutical company focused on developing antibody-based oncology therapies that completed its de-SPAC merger in 2022 with Brookline Capital Acquisition Corp, a blank-check vehicle sponsored by Brookline Capital Markets. The company filed an 8-K with the SEC on May 24, 2023, under accession number 0001193125-23-152387, continuing its reporting obligations as a publicly traded post-merger entity in the oncology sector. At the time of the filing, Apexigen remained active on the Nasdaq exchange, advancing therapeutic candidates targeting cancer biology through clinical development. For full filing history, sponsor details, and deal analytics on Apexigen and the broader SPAC universe, sign up for a free account at SpacDesk.